Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …

BACKGROUND: Considerable clinical data on the treatment of type 2 diabetes with incretin-
based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl …

Aims Preliminary data from randomized trials with metabolic outcomes have shown that
treatment with dipeptidyl peptidase‐4 inhibitors (DPP4i) could be associated with a reduced …

Abstract The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent
insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of …

Dipeptydil-peptidase-4 (DPP-4) inhibitors are available as oral anti-hyperglycemic drugs for
the treatment of type 2 diabetes. Their metabolic effect is mediated through sparing incretin …

The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile,
inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of …

Abstract Objective: Dipeptidyl peptidase-4 inhibitors (DPP4i) have been recently associated
with increased risk of pancreatitis and cancer. The aim of the present meta-analysis of …

We performed a review of the literature to determine whether the dipeptidyl peptidase-4
inhibitors (DPP4-I) may have the capability to directly and positively influence diabetic …